CD200R1 Gene

CD200R1 Gene

Introduction

CD200 Receptor 1 (CD200R1) is a cell surface glycoprotein belonging to the immunoglobulin superfamily that plays a critical role in maintaining immune tolerance and regulating inflammatory responses in the central nervous system (CNS). Originally identified as a receptor for the widely expressed CD200 glycoprotein, CD200R1 is primarily expressed on cells of the myeloid lineage, including microglia in the brain, macrophages, and certain subsets of dendritic cells [1](https://pubmed.ncbi.nlm.nih.gov/10820161/). The CD200-CD200R1 signaling axis represents one of the most important endogenous mechanisms for suppressing microglial activation and maintaining immunological quiescence in the healthy brain [2](https://pubmed.ncbi.nlm.nih.gov/17084427/).

The CD200R1 gene is located on chromosome 3q13.2 in humans and encodes a type I transmembrane protein with extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail containing multiple motifs that mediate inhibitory signaling. Unlike many other immune inhibitory receptors that signal through classical ITIM (immunoreceptor tyrosine-based inhibitory motif) sequences, CD200R1 employs a distinct signaling mechanism involving the recruitment of inhibitory adapter proteins that dampen downstream inflammatory pathways [3](https://pubmed.ncbi.nlm.nih.gov/14595437/).

CD200R1 Gene

Introduction

CD200 Receptor 1 (CD200R1) is a cell surface glycoprotein belonging to the immunoglobulin superfamily that plays a critical role in maintaining immune tolerance and regulating inflammatory responses in the central nervous system (CNS). Originally identified as a receptor for the widely expressed CD200 glycoprotein, CD200R1 is primarily expressed on cells of the myeloid lineage, including microglia in the brain, macrophages, and certain subsets of dendritic cells [1](https://pubmed.ncbi.nlm.nih.gov/10820161/). The CD200-CD200R1 signaling axis represents one of the most important endogenous mechanisms for suppressing microglial activation and maintaining immunological quiescence in the healthy brain [2](https://pubmed.ncbi.nlm.nih.gov/17084427/).

The CD200R1 gene is located on chromosome 3q13.2 in humans and encodes a type I transmembrane protein with extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail containing multiple motifs that mediate inhibitory signaling. Unlike many other immune inhibitory receptors that signal through classical ITIM (immunoreceptor tyrosine-based inhibitory motif) sequences, CD200R1 employs a distinct signaling mechanism involving the recruitment of inhibitory adapter proteins that dampen downstream inflammatory pathways [3](https://pubmed.ncbi.nlm.nih.gov/14595437/).

In the context of neurodegenerative diseases, the CD200-CD200R1 pathway has emerged as a critical therapeutic target.[@n2021] Both Alzheimer's disease (AD) and Parkinson's disease (PD) are characterized by chronic neuroinflammation driven by persistently activated microglia, and substantial evidence indicates that dysfunction in the CD200-CD200R1 axis contributes to this pathological microglial activation [4](https://pubmed.ncbi.nlm.nih.gov/25208678/). Restoring or enhancing CD200R1 signaling has therefore become an active area of drug development for neurodegenerative conditions [5](https://pubmed.ncbi.nlm.nih.gov/26228538/).

Gene Overview

<div class="infobox infobox-gene">
<h3>CD200R1</h3>
<table>
<tr><th>Full Name</th><td>CD200 Receptor 1</td></tr>
<tr><th>Symbol</th><td>CD200R1</td></tr>
<tr><th>Chromosomal Location</th><td>3q13.2</td></tr>
<tr><th>NCBI Gene ID</th><td>[131450](https://www.ncbi.nlm.nih.gov/gene/131450)</td></tr>
<tr><th>OMIM</th><td>[607410](https://www.omim.org/entry/607410)</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000163508</td></tr>
<tr><th>UniProt ID</th><td>[Q9Y6W5](https://www.uniprot.org/uniprot/Q9Y6W5)</td></tr>
<tr><th>Protein Class</th><td>Immunoglobulin superfamily, inhibitory receptor</td></tr>
<tr><th>Protein Size</th><td>436 amino acids (~50 kDa)</td></tr>
<tr><th>Expression</th><td>Microglia, macrophages, dendritic cells, T cells</td></tr>
<tr><th>Associated Diseases</th><td>Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Neuroinflammation</td></tr>
</table>
</div>

Protein Structure

CD200R1 is a type I transmembrane glycoprotein composed of 436 amino acids with a predicted molecular weight of approximately 50 kDa. The protein structure can be divided into several distinct domains:

Extracellular Domain: The extracellular region contains two immunoglobulin-like domains (Ig-like), each approximately 100 amino acids in length, connected by a short hinge region. The N-terminal Ig-like domain (D1) is responsible for ligand binding and interacts with CD200 with nanomolar affinity [6](https://pubmed.ncbi.nlm.nih.gov/11739500/). The second Ig-like domain (D2) provides structural support and contributes to receptor dimerization. The extracellular domains are heavily N-glycosylated, with multiple consensus N-linked glycosylation sites that influence protein folding and cell surface expression.

Transmembrane Region: A single hydrophobic transmembrane helix anchors the receptor in the plasma membrane. This region contains a positively charged arginine residue that may participate in interactions with negatively charged membrane lipids or adapter proteins.

Intracellular Domain: The cytoplasmic tail is approximately 140 amino acids in length and lacks a canonical ITIM motif found in many other inhibitory receptors. Instead, CD200R1 contains multiple tyrosine residues and proline-rich regions that serve as docking sites for signaling molecules. Key signaling motifs include:

• Tyrosine-based motifs that can be phosphorylated upon receptor engagement
• A potential PDZ domain-binding motif at the C-terminus
• Multiple serine and threonine residues that may serve as regulatory phosphorylation sites

Signaling Mechanism

The CD200R1 signaling pathway employs a distinctive mechanism distinct from classical inhibitory receptor signaling. Upon CD200 binding, CD200R1 undergoes conformational changes that enable recruitment of adaptor proteins:

DAP12 Association: CD200R1 can associate with the adapter protein DAP12 (DNAX-activating protein 12 kDa), which contains an ITAM (immunoreceptor tyrosine-based activation motif) in its cytoplasmic domain [7](https://pubmed.ncbi.nlm.nih.gov/14595437/). Paradoxically, despite DAP12 being an activating adapter, CD200R1 engagement leads to inhibitory signals due to the recruitment of additional negative regulators.

Negative Regulatory Pathways: CD200R1 signaling engages multiple downstream inhibitory pathways:

• PI3K/Akt pathway modulation: The receptor can activate PI3K signaling that promotes cell survival and anti-inflammatory phenotypes
• MAPK pathway inhibition: CD200R1 signaling dampens ERK and p38 MAPK activation in response to inflammatory stimuli
• NF-κB suppression: The receptor inhibits NF-κB nuclear translocation and transcriptional activity
• STAT signaling: CD200R1 can influence STAT1 and STAT3 phosphorylation states

• Ship1 (SHIP-1): An inositol phosphatase that hydrolyzes PIP3
• SHP-1: A protein tyrosine phosphatase that can dephosphorylate signaling intermediates
• Cbl-b: An E3 ubiquitin ligase that targets active signaling complexes for degradation

Expression Pattern

Cellular Expression

CD200R1 exhibits a restricted expression pattern primarily on cells of the myeloid lineage:

Microglia: CD200R1 is expressed at high levels on all microglia in the healthy brain [8](https://pubmed.ncbi.nlm.nih.gov/28650105/). Microglial expression of CD200R1 is essential for maintaining the surveillance phenotype and preventing spontaneous activation. Single-cell RNA sequencing studies have demonstrated that CD200R1 is expressed across all microglial subpopulations, including:

• Surveillance microglia (homeostatic microglia)
• Disease-associated microglia (DAM) - though with reduced expression
• Aged microglia

• Splenic macrophages
• Liver Kupffer cells
• Lung alveolar macrophages
• Skin dendritic cells

T Cells: Low-level CD200R1 expression has been detected on some T cell subsets, particularly regulatory T cells (Tregs) and certain memory T cells [9](https://pubmed.ncbi.nlm.nih.gov/19380871/).

Brain Region Expression

Within the brain, CD200R1 expression varies across regions:

• Cerebral cortex: Moderate microglial expression
• Hippocampus: High microglial expression, particularly in CA1 and dentate gyrus
• Basal ganglia: High expression in regions containing dopaminergic neurons
• Cerebellum: Moderate expression
• Brainstem: Variable expression across nuclei
• White matter: Lower expression compared to gray matter

Normal Physiological Functions

Maintenance of Microglial Quiescence

The CD200-CD200R1 axis is the primary endogenous mechanism maintaining microglial immunological quiescence in the healthy CNS [10](https://pubmed.ncbi.nlm.nih.gov/18218952/). The pathway operates through several mechanisms:

Baseline Inhibition: In the healthy brain, continuous CD200-CD200R1 signaling provides tonic inhibitory signals that:

• Suppress pro-inflammatory gene transcription
• Maintain surveillance phenotype
• Prevent spontaneous activation
• Inhibit phagocytic activity

• Attenuates TLR-mediated activation
• Reduces cytokine and chemokine production
• Limits reactive oxygen species generation
• Promotes tissue repair phenotypes

Immune Regulation

Beyond microglial regulation, CD200R1 participates in broader immune homeostasis:

Peripheral Tolerance: The receptor contributes to maintaining peripheral immune tolerance by:

• Regulating macrophage activation in peripheral tissues
• Modulating dendritic cell function
• Influencing T cell responses

Tissue Homeostasis

The CD200-CD200R1 pathway contributes to tissue homeostasis beyond immune regulation:

• Promotes neuronal survival in co-culture systems
• Supports oligodendrocyte function
• Modulates blood-brain barrier integrity

Disease Associations

Alzheimer's Disease

CD200-CD200R1 dysfunction is strongly implicated in Alzheimer's disease pathogenesis:

Evidence for Pathway Dysfunction:

• CD200 expression is reduced in AD brain tissue [12](https://pubmed.ncbi.nlm.nih.gov/19058866/)
• CD200R1 expression is altered on microglia in AD patients
• The ratio of CD200:CD200R1 shifts toward reduced signaling
• Post-mortem studies show decreased CD200R1 phosphorylation in AD brains

Therapeutic Implications:

• CD200R1 agonists are being developed to restore inhibitory signaling
• Gene therapy approaches to increase CD200 expression
• Small molecules that enhance CD200R1 downstream signaling

Parkinson's Disease

The CD200-CD200R1 pathway is highly relevant to Parkinson's disease:

Dopaminergic Neuron Vulnerability: CD200 is expressed on dopaminergic neurons, and loss of CD200-CD200R1 signaling contributes to:

• Increased microglial activation in the substantia nigra
• Enhanced vulnerability of dopaminergic neurons
• Chronic neuroinflammation in PD brain

• CD200R1 knockout mice show increased vulnerability to MPTP-induced parkinsonism [13](https://pubmed.ncbi.nlm.nih.gov/21224156/)
• CD200R1 activation protects against 6-OHDA toxicity
• AAV-mediated CD200 overexpression reduces microglial activation in PD models

• CD200R1 activation represents a neuroprotective strategy
• The pathway is downstream of several genetic risk factors for PD
• Combination approaches targeting multiple pathways are being explored

Multiple Sclerosis

CD200R1 dysfunction contributes to MS pathogenesis:

Demyelination and Inflammation: In MS:

• CD200 expression is reduced on oligodendrocytes and neurons
• CD200R1-expressing microglia fail to suppress inflammation
• Demyelination lesions show reduced CD200R1 signaling

• CD200R1-Fc fusion proteins (agonists)
• Cell-based therapies to restore the pathway

Amyotrophic Lateral Sclerosis (ALS)

Evidence for CD200R1 involvement in ALS:

• Microglial CD200R1 expression is altered in ALS models
• The pathway influences motor neuron vulnerability
• Restoring CD200R1 signaling is neuroprotective in SOD1 models [14](https://pubmed.ncbi.nlm.nih.gov/25761906/)

Other Neurodegenerative Conditions

Huntington's Disease: CD200R1 signaling is impaired in HD models Frontotemporal Dementia: Altered microglial CD200R1 expression Prion Disease: Pathway dysfunction contributes to disease progression

Therapeutic Development

Agonist Strategies

Several approaches are being developed to enhance CD200R1 signaling:

Recombinant CD200: Soluble CD200-Fc fusion proteins that activate CD200R1

• Pre-clinical studies show reduced neuroinflammation
• Improves cognitive function in AD models

• Higher specificity than CD200-based approaches
• Can be engineered for optimal pharmacokinetics

• Target downstream signaling pathways
• Orally bioavailable options

Gene Therapy

Viral vector-mediated approaches:

• AAV-CD200: Increases CD200 ligand availability
• Targets neurons and astrocytes to enhance CD200 expression
• Long-term expression potential

Cell-Based Therapies

Mesenchymal stem cells (MSCs):

• Express CD200 on their surface
• Transplanted MSCs can engage CD200R1 on microglia
• Promotes anti-inflammatory phenotype

Combination Approaches

Rational combinations under investigation:

• CD200R1 agonists with Aβ immunotherapy
• CD200R1 activation with tau-targeted therapies
• Anti-inflammatory approaches with neuroprotective agents

Animal Models

Knockout Mice

CD200R1 knockout mice exhibit:

• Spontaneous microglial activation
• Increased pro-inflammatory cytokine production
• Enhanced susceptibility to neuroinflammatory challenges
• Behavioral abnormalities

• Elevated baseline Iba1 staining in brain
• Increased CD68 expression
• Altered cytokine profiles
• Subtle cognitive deficits

Transgenic Models

Various disease models with CD200R1 modulation:

• 5xFAD mice with CD200R1 knockout
• MPTP-treated mice with CD200R1 agonists
• SOD1 mice with CD200R1 rescue

Therapeutic Studies

Preclinical evidence:

• CD200-Fc reduces amyloid burden in APP/PS1 mice [15](https://pubmed.ncbi.nlm.nih.gov/26228538/)
• CD200R1 agonist protects dopaminergic neurons in MPTP model
• Combination therapy shows synergistic effects

Research Methods and Models

Experimental Approaches

The study of CD200R1 in neurodegeneration employs multiple experimental methodologies:

In Vitro Models:

• Primary microglial cultures from rodent and human tissue
• iPSC-derived microglia and macrophages
• Co-culture systems with neurons, astrocytes, and oligodendrocytes
• Transwell assays to study paracrine signaling

• CD200R1 knockout mice (B6.129P2-Cd200r1tm1Yuz)
• CD200 transgenic mice
• Disease model crosses (APP/PS1, MPTP, 6-OHDA, SOD1)
• Conditional knockout models with Cre-lox systems

• RNA-seq of sorted microglia from CD200R1-manipulated mice
• ChIP-seq for transcription factor binding
• Proteomics to identify CD200R1 interactors
• Single-cell RNA sequencing of brain immune cells

• Two-photon microscopy of living brain
• Super-resolution microscopy of CD200R1 localization
• PET imaging with CD200R1-targeted tracers (in development)
• Light sheet microscopy for cleared tissue imaging

Biomarker Development

CD200R1-related biomarkers under development:

Fluid Biomarkers:

• Soluble CD200R1 (sCD200R1) in CSF and plasma
• CD200:CD200R1 ratio as pathway activity indicator
• Exosomal CD200R1 from microglia
• Cytokine profiles downstream of CD200R1

• [11C]CD200R1 PET ligands for microglial status
• MR-based approaches to detect neuroinflammation
• Optoacoustic probes for CD200R1

Clinical Translation

Challenges in translating CD200R1 research to clinic:

Species Differences: Mouse and human CD200R1 differ in:

• Ligand binding affinities
• Signaling cascade components
• Expression patterns
• Requires careful validation of mouse findings in human systems

• Blood-brain barrier penetration
• Target engagement in brain
• Sustained receptor activation
• Avoiding immune response to therapeutics

• Identifying patients who will benefit from CD200R1-targeted therapy
• Monitoring treatment response
• Dose optimization

Interaction Network

Protein Interactors

CD200R1 interacts with multiple proteins:

Direct Binding Partners:

• CD200 (canonical ligand)
• DAP12 (adapter protein)
• DAP10 (alternative adapter)
• SHP-1, SHP-2 (phosphatases)
• Ship1 (inositol phosphatase)
• Grb2 (adaptor protein)
• Cbl-b (E3 ubiquitin ligase)

• PI3K p85 subunit
• Akt/PKB
• mTOR complex components
• ERK1/2
• p38 MAPK
• JNK
• NF-κB pathway components
• STAT1, STAT3

Pathway Integration

CD200R1 intersects with multiple signaling pathways:

CD200R1
|
+---------+---------+
| |
DAP12 DAP10
| |
+----+----+ +----+----+
| | | |
Lyn PI3K Akt mTOR
| | | |
SHP-1 ---+--- mTORC1 Autophagy
| / \ | |
-NF-kB p-akt p-akt | |
| | | | |
Anti- Cell Anti- Protein Anti-
Inflam Survival Inflam Synth Inflam

Cellular Context

CD200R1 signaling varies by cell type:

Microglia:

• Strongest CD200R1 expression
• Constitutive signaling in healthy state
• Dysregulation in disease

• Context-dependent signaling
• Influenced by tissue environment
• Tumor-associated macrophage suppression

• Express CD200 ligand
• Use CD200R1 signaling for protection
• Activity-dependent CD200 expression

• Support CD200R1-microglia cross-talk
• Express CD200 under inflammatory conditions
• Modulate neuroinflammation indirectly

Clinical Perspectives

Patient Stratification

Future precision medicine approaches:

Genetic Factors:

• CD200R1 polymorphisms associated with disease risk
• Expression quantitative trait loci (eQTLs)
• Haplotype analysis

• Low CSF sCD200R1 indicates pathway dysfunction
• High CSF CD200 suggests ligand deficiency
• Peripheral monocyte CD200R1 as accessible marker

• Early intervention most promising
• Late-stage patients may have irreversible pathway loss
• Monitoring progression informs treatment timing

Combination Therapies

Rationale for combining CD200R1-targeted approaches:

With Immunotherapies:

• CD200R1 + Aβ antibodies: enhanced microglial clearance
• CD200R1 + tau immunotherapy: reduced spreading
• Synergistic anti-inflammatory effects

• CD200R1 + neurotrophic factors
• CD200R1 + mitochondrial protectants
• Enhanced neuronal survival

• CD200R1 + stem cell therapy
• CD200R1 + rehabilitation
• Optimized environment for regeneration

Economic Considerations

Healthcare economics of CD200R1-targeted therapies:

Cost of Current Care:

• Annual AD care: $321B in US (2024)
• PD care: $52B annually
• Major component is long-term care

• Disease modification: reduced progression
• Early intervention: delayed institutionalization
• Combination approaches: optimized efficacy

• Biomarker development
• Patient selection trials
• Long-term follow-up
• Justified by premium pricing potential

Future Directions

Emerging Research Areas

• Spatial transcriptomics of CD200R1+ cells
• Lineage tracing of microglial subsets
• Temporal dynamics of pathway changes

• Region-specific CD200R1 functions
• Neuron-microglia circuit modulation
• Circuit-specific therapeutic targeting

• CD200R1 aging phenotypes
• Rejuvenation strategies
• Intergenerational effects

• Sex-specific CD200R1 expression
• Hormonal modulation
• Personalized approaches

Unmet Needs

Critical questions remaining:

Implementation Roadmap

Translational pathway:

Phase 1 (Preclinical, 2024-2026):

• Validate novel agonists in humanized models
• Establish biomarker panels
• Complete IND-enabling studies

• First-in-human studies
• Dose-finding and safety
• Target engagement biomarkers

• Efficacy trials in early AD/PD
• Biomarker-driven patient selection
• Registration studies

• Real-world evidence collection
• Combination therapy studies
• Expanded indications

Allen Brain Atlas Data

Gene Expression

• Microglia - Highest expression of CD200R1 among brain cell types, consistent with its role as a myeloid cell marker
• Cerebral cortex - Low expression in cortical neurons
• Hippocampus - Low to moderate expression in hippocampal neurons
• Thalamus - Low expression in thalamic neurons

Single-Cell Expression

• Microglia: Highly expressed across all microglial subclusters
• Macrophages: Peripheral immune cells in the brain parenchyma
• Some dendritic cells: Minor population in the brain

Brain Region Expression Levels

External Resources

• [Human Brain Map - CD200R1 Expression](https://human.brain-map.org/microarray/search/show?search_term=CD200R1)
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/)
• [BrainSpan Transcriptome Atlas](https://brainspan.org/)

See Also

• [CD200 Gene](/genes/cd200)
• [CX3CR1 Gene](/genes/cx3cr1)
• [CSF1R Gene](/genes/csf1r)
• [TREM2 Gene](/genes/trem2)
• [Neuroinflammation Mechanism](/mechanisms/neuroinflammation-pathway)
• [Microglial Activation Mechanism](/mechanisms/microglial-phagocytosis)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed CD200R1 Literature](https://pubmed.ncbi.nlm.nih.gov/?term=CD200R1+neuroinflammation)
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/)
• [Allen Brain Atlas](https://brain-map.org/)
• [NIH Blueprint for Neuroscience Research](https://neuroscienceblueprint.nih.gov/)
• [Michael J. Fox Foundation for Parkinson's Research](https://www.michaeljfox.org/)

Pathway Diagram

References

Pathway Diagram

The following diagram shows the key molecular relationships involving CD200R1 Gene discovered through SciDEX knowledge graph analysis: